Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians

Bobby Shayegan, Frédéric Pouliot, Alan So, John Fernandes, Joseph Macri

Abstract


Androgen-deprivation therapy (ADT) is a standard of care in the treatment of advanced prostate cancer; however, testosterone monitoring practices for men undergoing ADT vary across Canada. Although a testosterone level of 1.7 nmol/L or lower has historically been defined as the accepted castrate level, newer assays with improved sensitivity have shown that both medical and surgical castration can suppress testosterone levels to below 0.7 nmol/L. This review explores the evidence supporting a redefinition of the castrate testosterone level as 0.7 nmol/L or lower, and presents results of a survey of testosterone monitoring practices among 153 Canadian urologists, uro-oncologists, and radiation oncologists who manage the treatment of men with hormone-sensitive prostate cancer.

Full Text:

PDF


DOI: http://dx.doi.org/10.5489/cuaj.4539

Comments on this article

View all comments
 |  Add comment